Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06355258

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

Led by Westlake University · Updated on 2024-11-12

80

Participants Needed

1

Research Sites

63 weeks

Total Duration

On this page

Sponsors

W

Westlake University

Lead Sponsor

S

Shaoxing Central Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are: * Does troxerutin lower the number of thrombotic events in participants? * What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients. Participants will: * Take troxerutin or a placebo every day for 7 days. * Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests * Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia

CONDITIONS

Official Title

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients aged 18 years and above
  • Confirmed COVID-19 infection by positive RT-PCR test
  • Mild COVID-19 defined as symptomatic without hypoxia or pneumonia
  • Severe COVID-19 defined as pneumonia signs with respiratory rate 60 breaths/min, severe respiratory distress, oxygen saturation 60% in room air, or worsening clinical symptoms with significant lung lesion progression
  • Written informed consent provided according to Chinese law (by patient, legal guardian, or deferred consent in emergencies)
Not Eligible

You will not qualify if you...

  • Pregnant or lactating women
  • Postpartum women within 6 weeks
  • Patients weighing over 100 kilograms
  • Clinical need for heparin therapy
  • Bleeding related to coagulation disorders, acute significant bleeding, active gastrointestinal ulcers, or lesions with high bleeding risk
  • Platelet count below 50 x 10^9/L
  • Surgery within last 15 days or within 24 hours after spinal or epidural anesthesia
  • History of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, or acute infective endocarditis
  • Severe renal impairment with creatinine clearance below 30 mL/min
  • Iodine allergy
  • Long-term use of oxygen supplementation
  • Moribund patients or expected death during current hospitalization due to underlying disease
  • Patients deprived of freedom or under institutional psychiatric care
  • Ward of the state or under guardianship
  • Participation in other anticoagulant intervention studies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shaoxing central hospital

Shaoxing, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

X

Xu Li, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here